Optimal Oncology Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-07-2024
- Paid Up Capital ₹ 0.10 M
as on 04-07-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Revenue -69.16%
(FY 2022)
- Profit -362.01%
(FY 2022)
- Ebitda -279.54%
(FY 2022)
- Net Worth -169.35%
(FY 2022)
- Total Assets -29.89%
(FY 2022)
About Optimal Oncology
The Corporate was formerly known as Harts Bridge Hospitals And Research Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Karthikeyan, Pradeep, and Raajes Dos serve as directors at the Company.
- CIN/LLPIN
U74999TN2019PTC127860
- Company No.
127860
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Mar 2019
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Optimal Oncology?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karthikeyan  | Director | 17-Sep-2020 | Current |
| Pradeep | Additional Director | 01-Dec-2022 | Current |
| Raajes Dos | Director | 05-Mar-2019 | Current |
Financial Performance of Optimal Oncology.
Optimal Oncology Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 69.16% decrease. The company also saw a substantial fall in profitability, with a 362.01% decrease in profit. The company's net worth observed a substantial decline by a decrease of 169.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Optimal Oncology?
In 2022, Optimal Oncology had a promoter holding of 42.50% and a public holding of 57.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Institute For Radio Imaging Studies And Research Private LimitedActive 5 years 10 months
Raajes Dos is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Optimal Oncology?
Optimal Oncology has a workforce of 1 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Optimal Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Optimal Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
